Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Appointed director
CC transcript
VION PHARMACEUTICALS INC (VION) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/08/2010 8-K Quarterly results
03/02/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Vion Pharmaceuticals, Inc. Monthly Operating Report filed with the United States Bankruptcy Court for the District of Delaware",
"Letter Agreement by and among Vion Pharmaceuticals, Inc. and the Official Committee of Unsecured Creditors filed with the United States Bankruptcy Court for the District of Delaware",
"VION PHARMACEUTICALS RECEIVES RESPONSE FROM FDA ON SPECIAL PROTOCOL ASSESSMENT FOR ONRIGIN&#212"
02/22/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "Vion Pharmaceuticals, Inc. Monthly Operating Report filed with the United States Bankruptcy Court for the District of Delaware"
02/18/2010 8-K Form 8-K - Current report
01/25/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "VION PHARMACEUTICALS ISSUES MANAGEMENT STATEMENT REGARDING TRADING VOLUME OF COMPANY'S COMMON STOCK"
01/08/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Vion Pharmaceuticals, Inc. Initial Monthly Operating Report filed with the United States Bankruptcy Court for the District of Delaware"
12/31/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "HOVON Trial As Designed Does Not Gain SPA Agreement"
12/16/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "VION PHARMACEUTICALS RECEIVES COMPLETE RESPONSE LETTER FOR ONRIGINÔ FROM THE U.S. FOOD AND DRUG ADMINISTRATION"
11/24/2009 8-K Form 8-K - Current report
10/13/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "VION PHARMACEUTICALS ENGAGES MERRIMAN CURHAN FORD TO EVALUATE STRATEGIC ALTERNATIVES"
09/09/2009 8-K Form 8-K - Current report
09/02/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "VION PHARMACEUTICALS ANNOUNCES RESULTS OF THE ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING FOR ONRIGIN&#212"
08/14/2009 8-K Conference call transcript
Docs: "VION PHARMACEUTICALS REPORTS 2009 SECOND QUARTER AND SIX-MONTH RESULTS",
"Transcript of August 13, 2009 Conference Call",
"VION PHARMACEUTICALS ANNOUNCES ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING FOR ONRIGIN&#212"
05/15/2009 8-K Quarterly results, Conference call transcript
Docs: "VION PHARMACEUTICALS REPORTS 2009 FIRST QUARTER RESULTS",
"Transcript of conference call held on May 14, 2009"
04/27/2009 8-K Form 8-K -- Current report
04/17/2009 8-K Form 8-K -- Current report
04/14/2009 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/13/2009 8-K Quarterly results, Conference call transcript
Docs: "VION REPORTS 2008 FULL-YEAR AND FOURTH-QUARTER RESULTS",
"Transcript of conference call held on March 11, 2009"
02/18/2009 8-K Form 8-K -- Current report
01/07/2009 8-K Form 8-K -- Current report
12/16/2008 8-K Form 8-K -- Current report
12/03/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "Vion Pharmaceuticals Adds Tanya Lewis to Senior Management Team NEW HAVEN, CT, December 2, 2008 — VION PHARMACEUTICALS, INC. today announced that Tanya Lewis had joined its senior management team as Vice President, Regulatory and Quality Affairs. Alan Kessman, Chief Executive Officer, said, ”We are extremely pleased to have Tanya Lewis joining Vion to head our regulatory and quality affairs efforts. She has extensive experience in these areas, and with a particular focus on oncology drugs, having played a significant role on the regulatory approvals for Velcade Ò .” He concluded, “She will lead our interactions with the U.S. Food and Drug Administration, starting with our effort to file a New Drug Application for laromustine with the FDA in early 2009.” Ms. Lewis commented, “I am excited about joining Vion and looking forward to working with the rest of the senior management team to pursue regulatory approval for laromustine in the United States.” Ms. Lewis has been advising Vion on re..."
11/10/2008 8-K Form 8-K -- Current report
10/17/2008 8-K Form 8-K -- Current report
09/23/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "COMPANY CONTACT:"
08/21/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "COMPANY CONTACT:"
08/18/2008 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Vion Pharmaceuticals is Delisted from Nasdaq Stock Market"
08/08/2008 8-K Conference call transcript
Docs: "VION REPORTS 2008 SECOND QUARTER AND SIX-MONTH RESULTS",
"Transcript of August 7, 2008 Conference Call"
07/18/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
06/30/2008 8-K Other Events
06/25/2008 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "Amendment No. 4 to Employment Agreement of Alan Kessman"
06/17/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "COMPANY CONTACT:"
06/04/2008 8-K Other Events, Financial Statements and Exhibits
Docs: "Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO Annual Meeting",
"Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine in Acute Myelogenous Leukemia at the ASCO Annual Meeting"
05/09/2008 8-K Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy